Clinical Trial Update: Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial comparing solabegron to placebo in women with overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Solabegron (solabegron)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Overactive Bladder | Phase 2 | Status: COMPLETED